Mode
Text Size
Log in / Sign up

Sub-Saharan Africa HIV programs show 73% awareness, 84% ART initiation, and 71% viral suppressionNew Data Shows Progress Toward HIV Treatment Goals for Youth

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that significant gaps in the UNAIDS cascade persist for AYA in sub-Saharan Africa, requiring targeted services.

This meta-analysis synthesized data from 37 studies to evaluate progress toward UNAIDS 95-95-95 targets among adolescents and young adults (AYA) living with HIV in sub-Saharan Africa. The analysis focused on three key metrics: awareness of HIV-positive status, initiation of antiretroviral treatment (ART), and achievement of viral load suppression.

For the total AYA population, the meta-analysis reported a 73% awareness rate, 84% ART initiation rate, and a 71% viral load suppression rate. Among the specific subgroup of AYA aged 15 to 24 years, the results showed 73% awareness, 83% ART initiation, and 82% viral load suppression. These figures indicate that while progress is being made, significant gaps remain in the clinical cascade for this demographic.

Clinical practice relevance is high as the data highlights persistent gaps in the UNAIDS cascade for AYA in sub-Saharan Africa. The authors suggest that programs must prioritize AYA-responsive services to improve outcomes. No specific limitations or safety data were reported in the source data.

A review of 37 studies in sub-Saharan Africa looked at how well young people and adolescents (AYA) are meeting specific global health goals for HIV care. These goals, known as the 95-95-95 targets, aim to ensure people know their status, start treatment, and achieve suppressed viral loads.

The data showed that 73% of these young people knew they were HIV positive. Among those who knew their status, 84% started antiretroviral treatment. However, only 71% of those on treatment achieved viral suppression. For the specific group of 15 to 24-year-olds, the rate of viral suppression was slightly higher at 82%.

While these numbers show progress, they also highlight where more work is needed. Because this is a large review of many different studies, the results show a general trend rather than a specific cause for these numbers. Patients and providers can use this information to see where programs need to focus more resources to help young people stay healthy.

What this means for you:
While many young people with HIV start treatment, more work is needed to ensure everyone achieves viral suppression.

Common questions

What percentage of young people with HIV are aware of their status?

The data shows that 73% of adolescents and young adults (AYA) in the studied regions were aware of their HIV-positive status. This figure remained consistent across the general group and the specific 15 to 24-year-old age bracket.

How many young people are starting antiretroviral treatment?

Among the young people who were aware of their HIV-positive status, 84% initiated antiretroviral treatment. For the specific group of 15 to 24-year-olds, the initiation rate was 83%.

What is the success rate for viral suppression in young adults?

The study found that 71% of all adolescents and young adults on treatment achieved viral suppression. For the 15 to 24-year-old age group, the rate of viral suppression was slightly higher at 82%.

Study Details

Study typeMeta analysis
Sample sizen = 19
EvidenceLevel 1
Follow-up288.0 mo
PublishedOct 2026
View Original Abstract ↓
OBJECTIVES: Tracking the progress of the Joint United Nations Programme on HIV/AIDS (UNAIDS) 95-95-95 targets is essential for evaluating HIV programme performance and improving outcomes across all subpopulations, age groups and geographical settings. We conducted a systematic review and synthesis of the UNAIDS 95-95-95 targets among adolescents and young adults (AYA) living with HIV in sub-Saharan Africa (SSA). DESIGN: The systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. DATA SOURCES: The search was conducted from the following databases: PubMed/MEDLINE, Embase, Scopus, CINAHL, African Index Medicus (AIM) and African Journals Online (AJOL) and grey literature sources. ELIGIBILITY CRITERIA: Articles that were published from 2015 to 2025 reported progress on at least one of the 95-95-95 targets were searched. We performed meta-analysis using WHO-defined AYA age bands (10-14, 15-19 and 20-24 years) and supplementary analysis of age bands of the included studies. DATA EXTRACTION AND SYNTHESIS: Full-text articles were downloaded from Rayyan software and data extraction was performed independently for each included study. We pooled independent study estimates and calculated 95% CIs intervals using random-effects models. Risk of bias was assessed at individual study level using the adapted Joanna Briggs Institute (JBI) tool. RESULTS: The search yielded 8435 articles, of which 220 were eligible for full-text screening and 37 were included. The studies originated from 13 (South Africa, Uganda, Botswana, Eswatini, Rwanda, Lesotho, Malawi, Cameroon, Democratic Republic of Congo, Ghana, Nigeria, Tanzania and Zimbabwe) SSA countries. The most reported age range 15-24 years (n=19, 51%). Half (n=18, 49%) of the studies reported one of three cascade outcomes and (n=13, 40%) all three. The progress toward UNAIDS target for all AYAs was 73-84-71, pooled proportion of those aware of their HIV-positive status was 73% (95% CI 65% to 81%), 84% (95% CI 77% to 91%) of diagnosed initiated antiretroviral treatment (ART) and 71% (95% CI 64% to 79%), those on ART achieved viral load suppression. The pooled proportion of HIV-positive diagnosed was 73% (95% CI 63% to 82%), 83% (95% CI 75% to 90%) ART initiated and 82% (95% CI 72% to 92%) viral load suppressed for 15-24 years old. CONCLUSION: Significant gaps persist throughout the UNAIDS cascade of AYA in SSA. To close these gaps, HIV programmes must prioritise AYA-responsive services that support earlier diagnosis, facilitate linkage and continuity of care and sustain long-term treatment engagement. Standardised definitions aligned with UNAIDS recommendations are essential. PROSPERO REGISTRATION NUMBER: CRD42024561024.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.